Breaking News

Aetna Inc AET Stock Humana Inc HUM Stock News

Aetna Inc (NYSE: AET) | Humana Inc (NYSE: HUM)

Aetna and Humana were both having a relatively normal day in the market today. When the market opened, both stocks started heading for the green. Throughout the day, they have both seen some green and some red, but nothing was exciting enough to write home about. Nonetheless, that all changed minutes ago as both stocks started to take a dive. Below, we’ll talk about what we’re seeing form AET and HUM, why, and what we’ll be watching for ahead.





What We’re Seeing From AET And HUM

As mentioned above, both Aetna and Humana were off to a relatively normal start to the day’s trading session. Throughout the session, both stocks have seen both the red and the green, but nothing exciting was happening. Nonetheless, that all changed minutes ago as both stocks started to take a dive. At the moment (11:44), AET and HUM are trading at $120.00 and $195.82 per share respectively after respective losses of $2.53 per share or 2.06% and $4.71 per share or 2.35% thus far today.

Why The Stocks Are Diving

As soon as the CNA Finance team received the alerts from Trade Ideas that AET and HUM were taking dives, we started digging to see exactly what was causing the movement. It didn’t take long to dig up the story, and it wasn’t a great one for either of the two companies involved. Ultimately, it seems as though the declines are being caused by merger news.


Minutes ago, Bloomberg released a report with regard to the massive merger between these two companies. Ultimately, it has been announced that a Federal Judge made the decision to block the deal, saying that it is anticompetative in nature. Ultimately, the merger between Aetna and Humana would have created somewhat of a monopoly, and the judge wasn’t going to have that. As a result, both stocks are falling as they react to the news.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on both AET and HUM. While the merger has been blocked in Federal Court, both companies have quite a bit going for them. We’re excited to hear about next moves following this news. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

DryShips DRYS Stock News

DryShips Inc. (NASDAQ: DRYS)

DryShips has been on an interesting ride in the market as of late, and today, that ride just got more interesting. When the opening bell rang, the stock was trading slightly in the red. From there, we’ve seen a continuation of declines, pushing it further and further into the abyss. Below, we’ll talk about what we’re seeing from DRYS, why, and what we’ll be watching for ahead.





What We’re Seeing From DRYS

As mentioned above, DryShips isn’t having the best of days in the market today, and for good reason (which we’ll get into below). When the opening bell rang, the stock was trading in the red. From there, the stock only continued falling, bringing the losses to the exponential level. In fact, at the moment (11:26), DRYS is trading at $6.25 per share after a loss of $1.83 per share or 22.65% thus far today.

Why The Stock Is Falling

As soon as our partners at Tradespoon informed us of the declines on DRYS, the CNA Finance team started digging to see if we could dig up the reason for the drop. In this case, it didn’t take long to find the news. In fact, it seemed to have just jumped out at us. Unfortunately, the declines seem to be the result of issues with the Securities and Exchange Commission (SEC).


According to recent reports, DryShips has made the mistake of lying to the regulatory agency. In fact, breaking news coming down the wire suggests that George Economou, CEO at the company, lied to the SEC in multiple 6-k filings. It is being alleged he was able to do so using Panama Papers proxy and corrupt Canadian officials. Of course, at the moment, there is an ongoing investigation and things aren’t looking too hot!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching DRYS incredibly closely. In particular, we’re interested in learning more about the alleged lies to the SEC and investors, and how this may play out. We’ll also be paying attention to ORIG, as Economou is the CEO of that company as well. Nonetheless, we’ll keep a close eye on the news and be sure to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 766
Synergy Pharmaceuticals SGYP Stock News

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals is having an incredibly rough day in the market today. Unfortunately, this is following up on the declines that we saw on Friday following the company’s approval from the FDA for Trulace (Plecanatide). Below, we’ll talk about what we’re seeing from SGYP, why, and what we’ll be watching for ahead.





What We’re Seeing From SGYP

As mentioned above, Synergy Pharmaceuticals isn’t having the best of days in the market today. In fact, when the opening bell rang, the stock was already trading well in the red. From there, we’ve seen a continuation of declines, bringing it’s value further and further into the abyss. At the moment (10:57), SGYP is trading at $5.58 per share after a loss of $0.33 per share or 5.58% thus far today.

Why The Stock Is Falling

This is a bit of a tricky one. As mentioned above, SGYP hasn’t done well in the market since Friday, when it was learned that the company had achieved FDA approval for Trulace (plecanatide). The approval was for the treatment of Chronic Idiopathic Constipation. In most cases, FDA approvals cause stocks to climb. However, in this particular case, that’s not what we’ve seen.


Ultimately, while the treatment was approved, there is one thing that’s proving to be concerning for Synergy Pharmaceuticals investors. Unfortunately, while the company has achieved approval, there’s a warning that comes with the approval. Some patients may experience severe diarrhea, and that will have to be part of the warning label on the treatment. In a statement, Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research had the following to say about the SGYP approval…

No one medication works for all patients suffering from chronic gastrointestinal disorders… With the availability of new therapies, patients and their doctors can select the most appropriate treatment for their condition.”

What We’ll Be Watching For Ahead

First and foremost, I would like to put it out there that I believe that concerns surrounding warning labels that will be used on Trulace are well overblown. In fact, the strongest treatment on the market at the moment has the same warning label, but didn’t perform quite as well on the efficacy side as Trulace. With that said, moving forward, the CNA Finance team is eager to learn about sales reports to see how the company does with regard to commercialization. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

Globus Maritime GLBS Stock News

Globus Maritime Ltd (NASDAQ: GLBS)

Globus Maritime is having yet another strong day in the market today, following up on recent gains. In fact, the stock has been trading up since a few days prior to President Trump’s inauguration. The questions now are why is trump sending the stock up, and will it last? Below, we’ll talk about what we’re seeing from GLBS, why, and what we’ll be watching for ahead.





What We’re Seeing From GLBS

As mentioned above, Globus Maritime has had a strong time in the market in recent trading sessions, and this session seems to be the same. At the opening bell, the stock found itself well in the green. While we have seen a bit of a correction in the early minutes of the session, the stock is still trading in the green, and likely to end the day on the strong note. In fact, at the moment (10:36), GLBS is trading at $10:05 per share after a gain of $0.35 per share or 3.61% thus far today.

Why the Stock Is Gaining

As mentioned above, GLBS has been on a strong run for several sessions in a row now, and it’s for a good reason. Ultimately, the gains that we’ve seen on the stock are part of a Trump-fueled rally, not only on this stock, but for the shipping sector as a whole. You see, Donald Trump is now the President of the United States. Throughout his campaign, one of the most important messages he has focused on is the changing of trade agreements.


At the moment, trade agreements are kicking international shipping companies in the United States down. In fact, in many cases, these shipping companies aren’t even capable of setting their own prices. However, Trump aims to change that, and in his early days in the office, he has already started the work on these agreements. As a result, Globus Maritime and other international shipping companies are creating a bit of excitement.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on GLBS and others in the shipping sector. Ultimately, we’ll be watching Trump’s moves with regard to trade agreements and how international shipping companies capitalize on the moves. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 458
Marinus Pharmaceuticals Inc MRNS Stock News

Marinus Pharmaceuticals Inc (NASDAQ: MRNS)

Marinus Pharmaceuticals is having an overwhelmingly strong day in the market today. When the trading session kicked off, the stock was already trading well into the green. From there it seems as though it has been on a mad-dash toward the top. Below, we’ll talk about what we’re seeing from MRNS, why, and what we’ll be watching for with regard to the stock ahead.





What We’re Seeing From MRNS

As mentioned above, Marinus Pharmaceuticals is off to an overwhelmingly strong start to the trading session today. When the opening bell rang, the stock found itself well into the green. From there, we’ve only seen a continuation of strong movement, pushing the value higher and higher. At the moment (10:02), MRNS is trading at $1.68 per share after a gain of $0.52 per share or 45.26% thus far today.

Why The Stock Is Gaining

As soon as we received the alert from Trade Ideas that MRNS was making a run for the top, the CNA Finance team started digging to see exactly what was causing the movement, In this case, it didn’t take long to uncover the story. Early this morning, the company announced positive preliminary data from the initial CDKL5 patients enrolled the company’s ongoing Phase 2 open-label study of ganaxolone as a treatment for orphan genetic disorders.


In the announcement Marinus Pharmaceuticals said that to date, 4 patients have been enrolled in this particular cohort. In the study, they have received up to 1,800 mg/kg of ganaxolone per day for an average treatment duration of five months. Of the four patients, three of them have experienced a notable reduction in seizure frequency when compared to baseline, ranging from 52% to 88%. The treatment has also shown to be generally safe and well tolerated. In a statement, Dr. Jaakko Lappalainen, Vice President of Clinical Development at MRNS had the following to offer…

We are encouraged by the results in these difficult-to-treat pediatric patients… Concurrent with completing this study, we will be evaluating the potential for breakthrough therapy and applying for orphan drug designation with the United States Food and Drug Administration. CDKL5 pediatric epilepsy may prove to be an attractive and efficient path for ganaxolone and we look forward to evaluating results from the final patients enrolled in this cohort of the study.”

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MRNS. In particular, we’re interested in following the study through the process. At the moment things are looking promising, making it more exciting to watch for finalized data. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikipedia]

Banc of California BANC Stock News

Banc of California Inc (NYSE: BANC)

Banc of California is having a rough start to today’s trading session. When the opening bell rang, the stock was trading well into the red. While we’ve seen some upward movement since the open of the session, it doesn’t look like the stock will get anywhere near ending the day in the green. Below, we’ll talk about what we’re seeing from BANC, why, and what we’ll be watching for ahead.





What We’re Seeing From BANC

As mentioned above, Banc of California is having an incredibly rough start to today’s trading session. As soon as the session opened, the stock was trading well into the red, thanks to pre-market activity. Since then, the stock has been trying to recover, inching upward, but it still looks like it will end the day in the red. At the moment, BANC is trading at $14.75 per share after a loss of $1.40 per share or 8.67% thus far today.

Why The Stock Is Down

As soon as our partners at Tradespoon sent us the signal that BANC was falling, the CNA Finance team started to work to see exactly what was causing the movement. In this particular case, it took no time at all to dig up the story. Early this morning, investors heard an important announcement from the company with regard to management.


This morning, the CEO of the company, Steven A. Sugarman, said that he would be resigning from his position. This is in light of recent uncovering of issues with the company and their potential dealings with a fraudster just months ago. At this point in time, investors haven’t been told who the incoming CEO will be as the company searches for a good match.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching BANC closely. In particular, we’re interested to see who the next CEO of the company will be and what early moves they make to remedy the issues that the company has been facing. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required











[Image Courtesy of Public Domain Pictures]

Hain Celestial Group HAIN Stock News

Hain Celestial Group Inc (NASDAQ: HAIN)

Hain Celestial Group was having what seemed to be a relatively normal day in the market today. As soon as the trading started for the session, the stock was in the green. However, it quickly fell to the red. From there, we saw some flat movement and a short attempt at a recovery. Nonetheless, things changed massively as the stock started spiking upward minutes ago. Below, we’ll talk about what we’re seeing from HAIN, why, and what we’ll be watching for ahead.





What We’re Seeing From HAIN

As mentioned above, Hain Celestial Group was having what seemed to be a normal day in the market. Starting the day in the green, falling to the red, and working to recover was the name of the game today. Nonetheless, the field changed minutes ago as the stock started to climb dramatically upward. Currently (11:20), HAIN is trading at $40.44 per share after a gain of $0.34 per share or 0.85% thus far today.

Why The Stock Is Climbign

In the case of HAIN, our partners at Trade Ideas sent the alert first. As soon as we got the news that the stock was on the run, the CNA Finance team started digging to see what was causing the movement. In this case, it didn’t take long at all to dig up the story. In our search, we were unable to find any fundamental news released by the company that would lead to such gains. However, we were able to find something interesting in the social space.


At the moment, it seems as though the gains on Hain Celestial Group are being caused by a rumor. The rumor is all over social media, stating that Pepsi is interested in acquiring the company. At this point, there has been no confirmation from either side that this is indeed the case. Nonetheless, it is exciting investors.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching HAIN incredibly closely. In particular, we’re interested in learning whether or not Pepsi is interested in acquiring HAIN. If this is the case, it could return incredible value to shareholders. However, this is yet another stock that seems to see these rumors quite often. So, don’t get your hopes up! Nonetheless, we’ll be watching the story closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

Harley-Davidson HOG Stock News

Harley-Davidson Inc (NYSE: HOG)

Harley-Davidson was off to what looked like it would turn out to be a rough day in the market today. When the trading session opened, the stock was trading in the red. From there, we saw slow movement, keeping the stock down. However, minutes ago, it started soaring, bringing it into the green. Below, we’ll talk about what we’re seeing from HOG, why, and what we’ll be watching for ahead.





What We’re Seeing From HOG

As mentioned above, Harley-Davidson wasn’t off to the best of starts to today’s trading session. In fact, at the opening bell, the stock was trading in the red. From there, throughout the morning, we saw a continuation of movement below the break-even point. Nonetheless, things changed in a big way minutes ago as the stock started spiking toward the top. At the moment (11:06), HOG is trading at $59.46 per share after a gain of $1.23 per share or 2.11% thus far today.

Why The Stock Is Spiking

When it comes to HOG, our partners at Tradespoon were the first to inform us of the spike. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to dig up the story. In our search, we weren’t able to find any fundamental news released by the company that would lead to such gains, but we were able to find something interesting in the world of social media.


At the moment, regardless of which social network is your favorite, if you go to it and search for Harley-Davidson, chances are that you’ll come across the rumor too. The rumor is that the company is going to be taken over. At the moment, the rumor is incredibly vague. We don’t believe that it will come to fruition. After all, in the past 3 months, we’ve seen rumors of HOG takeovers 4 times. Nonetheless, this seems to be what’s causing the excitement.

What We’ll Be Watching Ahead

Moving forward, the CNA Finance team will be keeping a close eye on HOG. In particular, we’re interested in seeing if there is any validity to this rumor. While we do not think there is, we could be wrong, and if it’s true, it could return incredible value to shareholders. Nonetheless, we’ll keep an eye on the story and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

Rite Aid Corporation RAD Stock News

Rite Aid Corporation (NYSE: RAD)

Rite Aid Corporation is having a rough start to the trading session today. When the session opened, the stock was already trading in the red. For the first hour, the stock was on a mad-dash downward. However, minutes ago, the stock was halted. Below, we’ll talk about what we’re seeing from RAD, why, and what we’ll be watching for ahead.





What We’re Seeing From RAD

As mentioned above, Rite Aide Corporation isn’t having a great day in the market today. In fact, when the opening bell rang, the stock was already trading in the red. Since then, we’ve seen dramatic downward movement, pushing the stock further and further into the abyss. However, minutes ago, the slide stopped when the stock was halted. Currently (10:40), RAD is trading at $8.09 per share after a loss of $0.51 per share or 5.93% thus far today.

Why The Stock Is Having Such A Rough Day

Our partners at Trade Ideas were the first to alert us of the movement on RAD. As soon as they did, the CNA Finance team started working to see if we could find the reason for the declines. In this particular case, it didn’t take long to dig up the story. While the stock is officially halted with “news pending”, we believe we have the news.

At the moment, information is surfacing with regard to the deal between Walgreens and Rite Aid. In fact, the idea is that the US FTC is not satisfied with this deal and that it may be blocked. Keep in mind that this is an ongoing breaking story. So, we simply don’t have all of the information for you… YET!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on RAD. In particular, we’re interested in seeing what happens with regard to the deal with Walgreens. If this deal is blocked, we could see further dramatic declines. Nonetheless, as mentioned above, the story is ongoing and breaking. We’ll bring you the updates as they break!

Update: RAD reopens. Currently (11:34), the stock is trading at $7.45 per share after a loss of $1.15 per share or 13.42% thus far today. Evercore says that if the deal doesn’t go through. Rite Aid could fall to $3.50 per share. Currently, there is no further news from the FTC. We will continue to watch the story closely and bring you the updates!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

Best Buy BBY Stock News

Best Buy Co Inc (NYSE: BBY)

Best Buy wasn’t necessarily off to the best of days in the market today. In fact, when the opening bell rang, the stock was already trading in the red. From there, we’ve seen a continuation of downward movement, bringing the stock further and further into the abyss. Nonetheless, it looks as though the stock is working to recover as it spikes following comments from the CEO. Below, we’ll talk about what we’re seeing from BBY, why, and what we’ll be watching for ahead.





What We’re Seeing From BBY

As mentioned above, Best Buy wasn’t having a great day in the market early on this morning. In fact, after starting the session off in the red, the stock continued to fall throughout the first half hour or so. However, minutes ago, comments from the CEO of the company broke, leading to an upward spike. At the moment, the stock is working to make it back to the green. Currently (10:13), BBY is trading at $43.33 per share after a loss of $0.30 per share or 0.69% thus far today.

Why The Stock Is Spiking

In the case of BBY, our partners at Tradespoon were the first to alert us of the spike on the stock. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this case, it didn’t take long to dig up the story at all. It seems as though the gains are the result of comments from the CEO of the company.


Early this morning, Hubert Joly, CEO at Best Buy had a discussion with Bloomberg. This follows reports that he would likely be stepping down from his position. However, in his comments today, Joly informed investors that he has no plans on leaving his position as CEO of the company. As a result, investors are excited, leading to the spike.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be watching BBY incredibly closely. Now that we know that Joly will maintain his position as CEO, it will be interesting to see his next steps. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

Thought Leader Discussions

Josh Disbrow head shot1 (1)

0 1503
Aytu Bioscience Inc (OTCMKTS: AYTU) Recently, the CNA Finance team had an opportunity to speak with Josh Disbrow, CEO of Aytu Bioscience. Josh Disbrow has...